A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic dermatitis not adequately controlled with topical ...
LEO Pharma Inc. announced today the availability of the Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in ...
Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...
Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market. However, ...
Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...
Verywell Health on MSN7d
Is Eczema an Autoimmune Disease or Something Else?While eczema does involve the immune system, most scientists wouldn’t classify eczema as an autoimmune disease. Autoimmune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback